Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Blanco, Salvatore ^a   Raber, Marco ^a   Leone, Biagio E ^b   Nespoli, Luca ^a   Grasso, Marco ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENDOSCOPIC SURGERY; FEMALE; FLUORESCENCE CYSTOSCOPY; HIGH RISK PATIENT; HUMAN; MALE; MALIGNANT TRANSFORMATION; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINARY TRACT MALFORMATION; BLADDER TUMOR; FLUORESCENCE; METHODOLOGY; PRECANCER;

CYSTOSCOPY; FLUORESCENCE; HUMANS; PRECANCEROUS CONDITIONS; URINARY BLADDER NEOPLASMS;

EID: 78549235104     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-122     Document Type: Article

References (30)

1. Grasso M. Bladder Cancer: a major public health issue. Eur Urol Suppl 2008, 7:510-5.
2. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997, 15:84. 10.1007/BF02201977, 9144896.
3. Koss LG. Mapping of the urinary bladder: its impact on concepts of bladder cancer. Hum Patol 1979, 10:533-548.
4. Murphy WM, Busch C, Algaba F. Intraurothelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol 2000, 205(Suppl):67-81.
5. Mostofi FK, Davis CJ, Sesterhenn I. Histological typing of urinary bladder tumours. World Health Organization international histological classification of tumours 1999, Berlin: Springer.
6. Soloway MS, Murphy W, Rao MK Cox C. Serial multiple-site biopsies in patients with bladder cancer. J Urol 1978, 120:57-59.
7. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990, 21:886-896. 10.1016/0046-8177(90)90171-Z, 2203672.
8. Bastacky S, Ibrahim S, Wlczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999, 87:118-128. 10.1002/(SICI)1097-0142(19990625)87:3<118::AID-CNCR4>3.0.CO;2-N, 10385442.
9. Kriegmair M, Knuchel R, Stepp H, Hofstaedter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996, 155:105-110. 10.1016/S0022-5347(01)66559-5, 7490803.
10. Jichlinski P, Forrer M, Mizeret J, et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 1997, 20:402-408. 10.1002/(SICI)1096-9101(1997)20:4<402::AID-LSM5>3.0.CO;2-U, 9142679.
11. Zaak D, Hungerhuber E, Schneede P, Stepp H, Frimberger D, Corvin S, Schmeller N, Kriegmair M, Hofstetter A, Knuechel R. Role of 5-Aminolevulinic Acid in the Detection of Urothelial Premalignant Lesions. Cancer 2002, 95:2580.
12. Colombo R, Naspro R, Bellinzoni P, et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther Clin Risk Manag 2007, 3(6):1003-7. 2387289, 18516260.
13. Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specifi city of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003, 44(1):51-6. 10.1016/S0302-2838(03)00210-0, 12814675.
14. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, . Hexvix PCB301/01 Study Group Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004, 171(1):135-8. 10.1097/01.ju.0000100480.70769.0e, 14665861, Hexvix PCB301/01 Study Group.
15. Algaba F, Amin M, et al. Tumours of the urinary system: non invasive urothelial neoplasias. WHO classification of tumours of the urinary system and male genital organs 2004, Lyon: IARCC Press, Eble JN, Sauter G, Epstein JI, Sesterhenn I.
16. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164(3 Pt 1):680-684. 10.1016/S0022-5347(05)67280-1, 10954628.
17. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes A, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49(3):466-477. 10.1016/j.eururo.2005.12.031, 16442208.
18. Fukui I, Yokokawa M, Sekine H, et al. Carcinoma in situ of the urinary bladder. Effect of associated neoplastic lesions on clinical course and treatment. Cancer 1987, 59:164-73. 10.1002/1097-0142(19870101)59:1<164::AID-CNCR2820590132>3.0.CO;2-Z, 3791145.
19. Lopez-Beltran A, Cheng L, Anderson L, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona international consultation. Virchows Arch 2002, 440:3-11. 10.1007/s00428-001-0577-6, 11942574.
20. Althausen AF, Prout GR, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976, 116:575-580.
21. Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 1994, 30A:1621-1615. 10.1016/0959-8049(94)E0133-O, 7833133.
22. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000, 88:625-631. 10.1002/(SICI)1097-0142(20000201)88:3<625::AID-CNCR20>3.0.CO;2-A, 10649257.
23. Cheng L, Chevilee JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999, 23:443-447. 10.1097/00000478-199904000-00009, 10199474.
24. Grossman HB. Improving the management of bladder cancer with fluorescence cystoscopy. J Environ Pathos Toxicol Oncol 2007, 26:143-7.
25. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007, 178:68-73. 10.1016/j.juro.2007.03.028, 17499291.
26. Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007, 178:62-7. 10.1016/j.juro.2007.03.034, 17499283.
27. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol 2003, 170:226-9. 10.1097/01.ju.0000060782.52358.04, 12796694.
28. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, König F, Knüchel R, Kurth KH. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter. J Urol 2005, 174(3):862-6. 10.1097/01.ju.0000169257.19841.2a, 16093971.
29. Kloek J, Akkermans W, Beijersbergen van Henegouwen GM. Derivatives of 5 aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 1998, 67:150. 10.1111/j.1751-1097.1998.tb05178.x, 9477773.
30. Marti A, Lange N, van den Bergh H, Sedmera D, Jichlinski P, Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 1999, 162:546. 10.1016/S0022-5347(05)68625-9, 10411086.